Abstract
Purpose
Dendritic cell (DC)-based cancer vaccines are currently being evaluated as novel anti-tumor vaccination strategies, but in some cases, they are demonstrated to have poor clinical efficacies than anticipated. A potential reason is immune tolerance due to the immunosuppressive enzyme, indoleamine-pyrrole 2,3-dioxygenase (IDO). The aim of this study was to determine whether blocking the activity of IDO might improve the anti-tumor efficacy of DC/Lewis lung carcinoma (LLC) fusion vaccine applied to the mouse LLC model.
Methods
To prepare the DC/LLC fusion vaccine, DCs were fused with LLC using polyethylene glycol (PEG) as described. The IDO expression in the DC/LLC fusion vaccine and in the vaccinated mice was detected by western blot (WB) and/or immunohistochemical (IHC) analysis. This fusion vaccine, as a single agent or in combination with 1-methyl-tryptophan (1-MT, an IDO inhibitor), was administered to LLC mice. The anti-tumor efficacy in different treatment was determined by regular observation of tumor development and the level of splenic cytotoxic T lymphocyte (CTL) response, which was examined by lactate dehydrogenase (LDH) release.
Results
In the LLC mice, we observed that IDO-positive cells were extensively accumulated in tumor draining lymph nodes (TDLNs). Furthermore, WB and IHC analysis results showed that vaccination with fusion DC/LLC cells alone caused significant up-regulation of IDO in spleens. 1-MT enhanced the anti-tumor efficacy elicited by DC/LLC fusion vaccine via delaying the tumor development and inducing stronger splenic CTL responses.
Conclusions
Our results indicate an IDO-mediated immunosuppressive mechanism might be involved in weakening the anti-tumor efficacy elicited by DC/LLC fusion vaccine, and specific inhibition of IDO activity might be required for development of cancer vaccines.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Immunotherapeutic strategies designed to prime anti-tumor T cells are currently under active clinical or pre-clinical development. Among them, dendritic cell (DC)-based cancer vaccine has been paid much attention as a new and cancer cell-specific therapeutic in the last decade. DCs, as the most potent antigen presenting cells (APCs), play a crucial role in triggering antigen-specific T cell responses because they are specifically equipped to engulf and process antigens and to present them to T cells (Banchereau and Steinman 1998; Shurin 1996). Several methods have been used for loading tumor antigens on DCs, including transduction of DCs with tumor antigen genes (Okada et al. 2005; Kirk et al. 2001; Wan et al. 1999), pulsing DCs with peptide antigen (Breckpot et al. 2004; Kono et al. 2002), and generation of DCs-tumor cell hybrids (Siders et al. 2003; Kao et al. 2003). However, the clinical outcome of most conventional DC vaccines tested to date has been less than anticipated (Vermij and Frei 2004; Shibata et al. 2006). One of the essential reasons for this is that the tumor-specific cytotoxic T lymphocytes (CTLs) in response to cancer vaccines become functionally inactive when they enter the tumor microenvironment (Steinbrink et al. 1999; Mukherjee et al. 2004). Immune escape, the ability of tumor cells to avoid destruction by the host immune system, is a major obstacle that must be addressed in designing and delivering a successful cancer vaccine (Basu et al. 2006).
An immune escape mechanism for tumors mediated by indoleamine-pyrrole 2,3-dioxygenase (IDO) has been recently discovered. IDO catalyses the initial and rate limiting step in the metabolism of an essential amino acid, tryptophan, along the kynurenine pathway (Takikawa et al. 1986). By depleting tryptophan, IDO blocks proliferation and activation of T lymphocytes, which are particularly sensitive to loss of tryptophan (Frumento et al. 2001; Mellor et al. 2002). Thus, IDO expression is involved in T cell suppression and induction of immune tolerance to tumors.
It has been reported that IDO is overexpressed in various tumor cells and APCs in response to the tumor (Munn and Mellor 2004; Uyttenhove et al. 2003; Hwu et al. 2000; Friberg et al. 2002), and that treatment with the IDO competitive inhibitor 1-methyl-tryptophan (1-MT) shows significant effects in reducing the incidence and progression of tumors in both preventive and therapeutic treatment models (Uyttenhove et al. 2003; Friberg et al. 2002; Muller et al. 2005a, b). However, since IDO is certainly not the only mechanism participating in these processes of tumor tolerance, simply inhibiting IDO is not likely to be sufficient (Munn 2006).
Emerging evidence suggests that IDO might be not only induce by the tumor, but also constitute a significant counter-regulatory mechanism induced by clinically relevant pro-inflammatory signals, such as IFN-gamma, IFN-alpha, CpG oligodeoxynucleotides, and 4-1BB ligation (Speiser et al. 2005; Seo et al. 2004; Nam et al. 2005; Mellor et al. 2005). More recently, Marion Wobser et al. (2007) reports that IDO is up-regulated in mature human DCs used in cancer immunotherapy, and predicts that IDO might contribute to the systemic immunological unresponsiveness and the failure of DC-based cancer immune therapies. These published data suggest that specific inhibition of IDO activity might be required for development of conventional or novel immune-based therapies.
In the present study, we sought to evaluate the anti-tumor efficacy of the DC/Lewis lung carcinoma (LLC) fusion vaccine applied to the mouse LLC model, a poorly immunogenic murine lung cancer model, as a single agent or in combination with 1-MT. The results demonstrated that the combination treatment was more effective than DC/LLC fusion vaccine alone in reducing tumor growth and inducing stronger CTL responses.
Materials and methods
Animals and cell lines
Four- to 5-week-old male C57BL/6 mice were purchased from Sun Yat-sen University (Guangzhou, China), and housed in a specific pathogen-free facility. All animal studies were conducted in accordance with institutional guidelines for the care and use of experimental animals. The LLC cell line, which was originally derived from a C57BL/6 mouse, was cultured in complete medium (CM) consisting of Dulbecco’s Modified Eagle’s Medium (Gibco BRL, Gaithersburg, MD, USA) supplemented with 10% fetal bovine serum (FBS), l-glutamine, and antibiotics.
Western blot (WB) analysis
Ten days after C57BL/6 mice were subcutaneously injected with LLC cells (1 × 106), tumors and lymphoid organs were homogenized in 0.5 ml of lysis buffer containing 1% Nonidet P-40, 20 mM Tris–HCl (pH 7.6), 0.15 M NaCl, 3 mM EDTA, 3 mM EGTA, 1 mM PMSF, 2 mM sodium vanadate, 20 mg/ml aprotinin and 5 mg/ml leupeptin as described (Du et al. 2004). Insoluble material was removed by centrifugation (12,000 rpm 30 min, 4°C). The soluble cell lysates were separated on 10% SDS-PAGE, and blotted onto a polyvinylidene fluoride (PVDF) membrane (Bio-Rad). After nonspecific binding was blocked by incubating with 5% non-fat dry milk, the membrane was incubated with the anti-IDO monoclonal antibody (1:1,000, Chemicon, Temecula, CA, USA) at 4°C overnight and then with a HRP-conjugated anti-mouse IgG (1:5,000, Boster, China). The resulting signal was detected by ECL Western blot method (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and the loading control was β-actin (1:5,000, Cell Signaling Technology, Beverly, MA, USA).
Immunohistochemical (IHC) analysis for IDO expression
The tumors and lymphoid organs were fixed in formalin, embedded in paraffin, and the paraffin blocks were sectioned. Sections were deparaffinized and then incubated with anti-IDO monoclonal antibody (1:50; Chemicon) overnight at 4°C. An isotype-matched irrelevant antibody (1:50, Santa Cruz) was used as the negative control. After three washes with PBS, slides were incubated with the HRP-labeled polymer conjugated secondary antibody (EnVision+; DAKO, Copenhagen, Denmark), and DAB (DAKO) was applied as a substrate. The slides were rinsed in distilled water and counterstained with hematoxylin (Sigma-Aldrich, St. Louis, MO, USA).
Generation of bone marrow-derived DCs
Erythrocyte-depleted murine bone marrow cells obtained from the femur were cultured in CM supplemented with rmGM-CSF (10 ng/ml; PeproTech, London, UK) at 1 × 106 cells/ml (Kao et al. 2003). The cytokines were replenished on day 3. On days 6–8, non-adherent DCs were harvested by vigorous pipetting for further use.
DC/tumor fusion cell preparation
Bone marrow-derived DCs were fused with tumor cells at a DC-to-tumor cell ratio of 3–1 using 50% polyethylene glycol (PEG, MW 1,450)/DMSO solution (Sigma-Aldrich), as described (Wang et al. 1998). Briefly, the DC/tumor cell suspension was washed twice with RPMI-1640 (pre-warmed to 37°C). PEG (50%, 0.5 ml, pre-warmed to 37°C) was added over 1 min and the suspension was stirred gently for 1 min. Pre-warmed RPMI-1640 (1 ml) was then added over 1 min and the suspension was stirred. An additional 3 ml of RPMI-1640 was added over 3 min, after which 10 ml of RPMI-1640 was added slowly with consistent stirring. After 5 min of incubation at 37°C, the resultant cell mixture was pelleted and grown overnight in CM with 10 ng/ml GM-CSF. The fusion cells were irradiated (10,000 rads) to render them non-proliferative before being injected into mice. Co-cultured groups were identically prepared except that PEG was omitted.
Immunofluorescence analysis
For phenotype analysis, cells were washed with PBS and incubated with mAb anti-CD40, mAb anti-CD80, mAb anti-CD86 (BioLegend, San Diego, CA, USA), or mAb anti-MHC class II (eBioscience, San Diego, CA, USA) for 30 min on ice. After washing with PBS, cells were analyzed by flowcytometry.
To evaluate the fusion efficiency, tumor cells were identified by staining 106/ml cells with 2 μg/ml 3,3-dioctadecyloxacarbocyanine perchlorate (DiOC18; Invitrogen Life Technologies, Carlsbad, CA, USA) for 30 min at 37°C in PBS as previously described (Wang et al. 1998). The labeled cells were washed three times with PBS and fused with DCs as described above. Fusion preparations were further stained with FITC-conjugated anti-CD11c antibody (BioLegend). After three washes with PBS, cells were analyzed by flowcytometry.
Character of DC/LLC fusion vaccine and its effect on IDO induction in mice
To determine whether the DC vaccine affects IDO activity, 1 × 106 DCs, DC/LLC fusion cells, and DC + LLC mixture cells lysed, respectively and subjected to WB analysis with monoclonal IDO antibody as described above. Additionally, 1 × 106 non-proliferative DC/LLC fusion cells and DC + LLC mixture cells (fusion mock control) were s.c. injected into mice respectively twice within a 7-day interval. One week after the second injection, spleens from the vaccinated mice were removed and screened for IDO expression by WB and IHC analysis.
Treatment of mice with DC/LLC fusion vaccine and IDO inhibitor 1-MT
Four- to 5-week-old male C57BL/6 mice were randomized into the following four groups: Group 1 (n = 12): PBS treated controls; Group 2 (n = 12): vaccinated with DC/LLC fusion cells (1 × 106 non-proliferative cells per s.c. injection twice within a 7-day interval); Group 3 (n = 12): treatment with 1-MT (Sigma-Aldrich; begun 1 week prior to tumor implantation; twice a day by mouth for 2 weeks; 400 mg/kg, dissolved in 1% Tween 80/0.5% methylcellulose (TMC) and stirred continuously to get a fine suspension); Group 4 (n = 12): treated with DC/tumor fusion cells and 1-MT. A schematic of the treatment regimen used is depicted in Fig. 5a. One week after the second DC vaccination, 1 × 106 LLC cells were injected s.c. into the flanks of the mice. Animals were checked for tumors twice weekly. Tumor size was measured in two perpendicular dimensions with a pair of vernier calipers. Tumor volume was determined by the following formula: volume = (a × b 2)/2, where a is the largest diameter of the tumor and b is the smallest diameter.
Cytotoxicity assays
One week after the second vaccination, spleens were removed from two mice randomly selected from each group for preparation of single-cell suspensions by pressing against fine nylon mesh. Red cells were lysed using 0.84% ammonium chloride. Spleen lymphocytes were co-cultured with mitomycin C (50 μg/ml)-treated LLC cells at 25:1 in RPMI 1640 plus 10% FBS. Five days later, cytotoxicity assay was conducted using non-radioactive lactate dehydrogenase (LDH) release using a cytotoxicity detection kit (CytoTox 96, Promega, Madison, WI, USA) as the manufacturer’s instructions. Spontaneous release and maximum release were determined by incubating target cells without effector cells in medium alone or in 0.5% NP40, respectively. The percent cytotoxicity was calculated as follows: (experimental release − spontaneous release)/(maximum release − spontaneous release) × 100%.
Statistical analysis
Student t-test was used to evaluate the significance of differences between experimental groups. Between-group differences in percentage of tumor-free individuals were evaluated using the Log-Rank test. Statistical tests were two-sided. P values less than 0.05 were considered to be statistically significant.
Results
IDO is expressed by mononuclear cells within tumor draining lymph nodes and spleens
Western blot and IHC analyses were carried out to determine whether the immunosuppressive enzyme IDO is expressed within LLC tumors or tumor draining lymph nodes (TDLNs). The tumors and TDLNs were removed from the inguinal region and divided into two aliquots: one for WB and one for IHC analysis. The distant lymph nodes (DLNs), the axillary lymph nodes, were also isolated. As shown in Fig. 1a, 10 days after tumor cell injection, IDO was strongly expressed in the TDLNs, weakly expressed in the tumor parenchyma, and not detectable in the DLNs. To check whether this tumor cell line can express IDO, LLC were treated with rm-IFN-γ (PeproTech), at a concentration well known to induce expression of IDO. WB analysis of the resultant LLC lysates found no IDO expression (Fig. 1b). Thus, tumor cells directly or indirectly induce IDO expression in other cells but not in themselves. Additionally, IHC analysis showed that IDO-positive cells were extensively accumulated in reticular region of TDLNs (Fig. 2d), while scattered and sparse within the tumor parenchyma (Fig. 2b), but not in DLNs from the same mouse (Fig. 2c). Together, these results indicated that non-malignant cells rather than tumor cells themselves produced IDO.
Immunofluorescence analysis of DC/LLC fusion cells
Lewis lung carcinoma cells were fused with bone marrow-derived DCs to enhance the T lymphocyte-mediated immunity to the weakly immunogenic tumor. The DCs were stained with FITC-conjugated anti-mouse CD11c (a green membrane marker) and LLC cells were labeled with DiOC18 (a red membrane marker). Flow cytometry found 22.1% double-positive cells after DC/LLC fusion (Fig. 3a). This is consistent with the reported fusion efficiencies of 10–30% (Jantscheff et al. 2002; Xia et al. 2005). In contrast to the tumor cells, DCs expressed MHCII and costimulatory molecules (CD80 and CD86) (Fig. 3b), as did the DC/LLC fusion products.
DC/LLC fusion cells did not express IDO, but induced IDO up-regulation in the spleens of vaccinated mice
To explore whether vaccination with DC/LLC fusion cells affects IDO-mediated immunosuppression, IDO expression was measured in DCs, DC/LLC fusion cells, and the immune organs of vaccinated mice. As shown in Fig. 4a, IDO was not expressed in bone-marrow derived DCs cultured in vitro, DC/LLC fusion cells, or DC + LLC mixed cells (Fig. 4a). However, vaccination with fusion cells up-regulated IDO expression in the spleens of the vaccinated mice (Fig. 4a). IHC identified these cells as non-malignant mononuclear cells (Fig. 4b).
The synergistic effect of DC/LLC fusion cells combined with 1-MT on delaying tumor growth
Since we hypothesized that expression of IDO by mononuclear cells infiltrating the tumors and immune organs might prevent immune-mediated rejection of LLC tumors, the combination of DC/LLC fusion cells and IDO specific inhibitor, 1-MT, was tested to determine whether it was more effective than its component parts. C57BL/6 mice were randomly assigned to four groups as described in “Materials and methods”. One week after the final vaccination, mice were challenged by local s.c. injection of 1 × 106 LLC tumor cells, and the growth was assessed at regular intervals by a blinded observer to determine therapeutic efficacy. Tumors developed in the first week and grew progressively in 60% of mice immunized with PBS (Fig. 5b). Tumor growth was evidently decreased in mice immunized with DC/LLC fusion cells (P < 0.05) or 1-MT (P < 0.05) in contrast to the PBS control group in day 27 after tumor challenge. However, mice treated with combination showed a significant reduction (P < 0.001) in tumor development. Compared with the mice vaccinated with DC/LLC fusion vaccine alone, the combination treatment was also able to delay the tumor outgrowth (P < 0.05) (Fig. 5c). These results demonstrated that 1-MT could enhance DC/LLC fusion vaccine-induced protective immunity against tumor challenge.
1-MT with DC/LLC fusion vaccine induced cytotoxic T lymphocyte responses
To determine the effect of the combination on host T cell responses, CTL activity analysis was performed. LDH release assays showed that the combination treatment elicited stronger CTL activity (29.23 ± 2.37%, E:T = 50:1) than DC/LLC treatment alone (19.33 ± 2.37%, P < 0.01) and the PBS control treatment (6.53 ± 2.00%, P < 0.001) (Fig. 6). A separate experiment found similar results. Thus, the combination treatment induced stronger CTL responses against LLC cells.
Discussions
Tumors suppress anti-tumor immunity through several pro-tolerogenic mechanisms. Among them, IDO has recently been identified as an impediment to successful cancer immunotherapy. IDO can be expressed by tumor cells and by other non-malignant cells in response to the tumor (Uyttenhove et al. 2003; Friberg et al. 2002). Abnormal expression of IDO in tumor cells has been shown to be inducible by IFN-γ and inhibit local T-cell responses (Taylor and Feng 1991), and tumor cells transfected with IDO become resistant to immunologic rejection, even in mice that have been pre-immunized against the tumor (Uyttenhove et al. 2003). The induction of IDO could also occur in nonmalignant cells either in direct proximity or at more distal sites, such as the DCs in the TDLNs (Friberg et al. 2002), probably via B7 ligation by regulatory T cells (Treg) (Fallarino et al. 2003). Since TDLNs are the primary sites for immune system to encounter tumor antigens (Spiotto et al. 2002), it has been argued that this might even be the principal means of establishing tolerance (Munn and Mellor 2004).
The preceding discussion has focused on IDO expression related to the tumor, however, the IDO expression relevant to the anti-tumor immune response provoked by clinical immunotherapy is still not elucidated well. In this report, we used the LLC mouse model, in which two remarkable features were observed. Firstly, IDO-positive cells were extensively accumulated in TDLNs, but scattered and sparse within the tumor parenchyma in the tumor bearing mice. These cells were most likely APCs such as DCs or macrophages (Muller et al. 2005a, b). More importantly, prior to tumor implantation, vaccination with DC/LLC fusion cells alone also caused significant up-regulation of IDO in spleens, though IDO was undetectable in vitro both in mature bone marrow-derived DCs or in DC/LLC fusion cells. It is well known that IDO could be induced by IFN-α and IFN-γ, which are secreted by activated T cells in response to any successful tumor-immunotherapy strategy, while expression of IDO might be an important event for altering T cell clonal expansion environment, causing T cell anergy. Therefore, in the present study, this IDO up-regulation in spleens is supposed to be an inflammation-induced counter-regulatory responses, which are utilized to limit the immune reactions of activated T cells elicited by the DC/LLC fusion vaccine.
Counter-regulatory responses are important in the immune system and they help to limit the intensity and extent of strong immune responses, which otherwise could result in dangerous collateral damage to the host (Munn 2006). However, when it comes to tumor immunotherapy, this negative regulation might have the potential to antagonize the effects of other immunotherapy approaches desire to prime anti-tumor T cells.
Thus, to improve the anti-tumor efficacy of tumor immunotherapy, it should be helpful to add an IDO inhibitor to the conventional immune treatment scheme to overcome IDO-mediated immune tolerance. In our study, 1-MT enhanced reduction of tumor growth and induction of splenic CTLs in response to the DC/LLC fusion vaccine alone. There are two reasons: (1) 1-MT inhibited IDO-mediated immune suppressive microenvironment, in the tumor tissue and TDLNs and (2) 1-MT blocked the IDO-mediated counter-regulatory responses induced by the DC/LLC fusion vaccine. Thus, the anti-tumor T cells activated by the DC vaccine were allowed to clonally expand and became more effective once migrating into the tumor parenchyma.
It is indubitable that the efforts to improve the immunotherapeutic strategies should be focused on more efficient T cell activation and better generation of tumor-specific killer T cells (Lee 2002; Hatakeyama et al. 2006). However, the status of microenvironment for activated T cells to take effects is also should be concerned on. Ineffective cancer vaccines in clinical trial (Rosenberg et al. 2004; Gajewski et al. 2006) suggest that CTLs directed against the tumor might become functionally inactive when they enter the tumor microenvironment. Malignant tumors have been shown to evade T cell-mediated rejection by producing a variety of immunosuppressive proteins including IL-10, TGF-β and Fas ligand (Chouaib et al. 1997), while in the present work, we proved the IDO expression in non-malignant cells in immune organs, caused by the tumor as well as some clinical immunotherapy, could also contribute to the suppression of anti-tumor T cell response via the tryptophan depletion.
Additionally, in this experiment, we also found some inflammation at mucosal surfaces in oral cavity in mice, where encounter with non-pathogenic bacteria and non-harmful foreign antigens was frequent (unpublished data). Some other researchers reported that blocking IDO activity in either autoimmune colitis (Gurtner et al. 2003) or autoimmune asthma (Hayashi et al. 2004), significantly worsened the severity of disease. Besides, Munn and Mellor reported that pregnant mice exposed to IDO inhibitor exhibited dramatically increased tendencies to lose conceptuses in allogeneic but not syngeneic mating combinations (Munn et al. 1998; Mellor and Munn 2000; Mellor et al. 2001). These data suggest that IDO might play a physiological role in regulating immune responses and the specific route of administration of 1-MT remains to be developed.
In summary, our results suggest that 1-MT could enhance the anti-tumor efficacies of other immunotherapeutic approaches by helping to break tumor tolerance and removing undesired counter-regulation.
References
Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252
Basu GD, Tinder TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA, Mukherjee P (2006) Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 177:2391–2402
Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K (2004) Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol 172:2232–2237
Chouaib S, Asselin PC, Mami CF, Caignard A, Blay JY (1997) The host-tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 18:493–497
Du J, Cai SH, Shi Z, Nagase F (2004) Binding activity of H-Ras is necessary for in vivo inhibition of ASK1 activity. Cell Res 14:148–154
Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P (2003) Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 4:1206–1212
Friberg M, Jennings R, Alsarraj M, Dessureault S, Cantor Alan, Extermann M, Mellor AL, Munn DH, Antonia SJ (2002) Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101:151–155
Frumento G, Rotondo R, Tonetti M, Ferrara GB (2001) T cell proliferation is blocked by indoleamine 2,3-dioxygenase. Transplant Proc 33:428–430
Gajewski TF, Meng Y, Harlin H (2006) Immune suppression in the tumor microenvironment. J Immunother 29:233–240
Gurtner GJ, Newberry RD Schloemann SR, McDonald KG, Stenson WF (2003) Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 125:1762–1773
Hatakeyama N, Tamura Y, Sahara H, Suzuki N, Suzuki K, Hori T, Mizue N, Torigoe T, Tsutsumi H, Sato N (2006) Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells. Exp Hematol 34:197–207
Hayashi T, Beck L, Rossetto C, Gong X, Takikawa O, Takabayashi K, Broide DH, Carson DA, Raz E (2004) Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J Clin Invest 114:270–279
Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA (2000) Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 164:3596–3599
Jantscheff P, Spagnoli G, Zajac P, Rochlitz CF (2002) Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells. Cancer Immunol Immunother 51:367–375
Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ (2003) Tumor derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine. J Immunol 170:3806–3811
Kirk CJ, Hartigan O’CD, Nickoloff BJ, Chamberlain JS, Giedlin M, Aukerman L, Mule JJ (2001) T cell dependent anti tumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell based immunotherapy. Cancer Res 61:2062–2070
Kono K, Takahashi A, Sugai H, Fujii H, Choudhury AR, Kiessling R, Matsumoto Y (2002) Dendritic cells pulsed with HER-2/neuderived peptides can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 8:3394–3400
Lee SP (2002) Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy. Semin Cancer Biol 12:463–71
Mellor AL, Munn DH (2000) Immunology at the maternal–fetal interface: lessons for T cell tolerance and suppression. Annu Rev Immunol 18:367–391
Mellor AL, Sivakumar J, Chandler P, Smith K, Molina H, Mao D , Munn DH (2001) Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2:64–68
Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH (2002) Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol 168:3771–3776
Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH (2005) Cutting Edge: CpG Oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J Immunol 175:5601–5605
Mukherjee P, Tinder TL, Basu GD, Pathangey LB, Chen L, Gendler SJ (2004) Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model. Breast Dis 20:53–63
Muller AJ, Duhadaway JB, Donover PS, SutantoWE, Prendergast GC (2005a) Inhibition of indoleamine 2, 3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11:312–319
Muller AJ, Malachowski WP, Prendergast GC (2005b) Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors. Expert Opin Ther Targets 9:831–849
Munn DH (2006) Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 18:220–225
Munn DH, Mellor AL (2004) IDO and tolerance to tumors. Trends Mol 10:15–18
Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL (1998) Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191–1193
Nam KO, Kang WJ, Kwon BS, Kim SJ, Lee HW (2005) The therapeutic potential of 4-1BB (CD137) in cancer. Curr Cancer Drug Targets 5:357–363
Okada N, Iiyama S, Okada Y, Mizuguchi H, Hayakawa T, Nakagawa S, Mayumi T, Fujita T, Yamamoto A (2005) Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Cancer Gene Ther 12:72–83
Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–15
Seo SK, Choi JH, Kim YH, Kang WJ, Park HY, Suh JH, Choi BK, Vinay DS, Kwon BS (2004) 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nat Med 10:1088–1094
Shibata S, Okano S, Yonemitsu Y, Onimaru M, Sata S, Nagata T H, Inoue M, Zhu T, Hasegawa M, Moroi Y, Furue M, Sueishi K (2006) Induction of efficient antitumor immunity using dendritic cells activated by recombinant sendai virus and its modulation by exogenous IFN-β gene. J Immunol 177:3564–3576
Shurin MR (1996) Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 43:158–164
Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM (2003) Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 7:498–505
Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115:739–746
Spiotto MT, Yu P, Rowley DA, Nishimura MI, Meredith SC, Gajewski TF, Fu YX, Schreiber H (2002) Increasing tumor antigen expression overcomes ‘‘ignorance’’ to solid tumors via cross presentation by bone marrow-derived stromal cells. Immunity 17:737–747
Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH (1999) Interleukin-10-treated human dendritic cells induce a melanoma-antigen-anergy in CD8(+) T cells resulting in a failure to lyse tumour cells. Blood 93:1634–1642
Takikawa O, Yoshida R, Kido R, Hayaishi O (1986) Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. J Biol Chem 261:3648–3653
Taylor MW, Feng G (1991) Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 5:2516–2522
Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9:1269–1274
Vermij P, Frei M (2004) Halted trial renews questions about cancer vaccines. Nat Med 10:3
Wan Y, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, Gauldie J (1999) Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 198:131–138
Wang J, Saffold S, Cao X, Krauss J, Chen W (1998) Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 161:5516–5524
Wobser M, Voigt H, Houben R, Eggert AO, Freiwald M, Kaemmerer U, Kaempgen E, Schrama D, Becker JC (2007) Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression. Cancer Immunol Immunother 56:1017–24
Xia D, Chan T, Xiang J (2005) Dendritic cell/myeloma hybrid vaccine. Methods Mol Med 113:225–233
Acknowledgments
This work was supported by National Natural Science Foundation in China (No. NSFC-30471978, and No. NSFC-30672510) and Natural Scientific Foundation of Guangdong Province (Grant code: 5001771).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ou, X., Cai, S., Liu, P. et al. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. J Cancer Res Clin Oncol 134, 525–533 (2008). https://doi.org/10.1007/s00432-007-0315-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-007-0315-9